Contributions of GsCouplingGil

Contributions by GsCouplingGil, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 1,544 edits includes activity predating the current log.

1. 17:57, 19 May 2026 (diff | hist) FLOW trial 4,583 ±0 rm the cross-trial comparison; the populations are not comparable
2. 19:46, 12 Apr 2026 (diff | hist) Beta cell function 6,096 ±0 m unpipe a link that did not need piping
3. 15:20, 11 Apr 2026 (diff | hist) Talk:Tirzepatide 748 +206 /* Is "GIP-biased" the right term? */ reply
4. 09:33, 20 Mar 2026 (diff | hist) Gastric emptying 5,565 ±0 expand §Normal physiology
5. 15:00, 3 Mar 2026 (diff | hist) Glucagon-like peptide-1 12,294 ±0 m attribute the receptor-density claim to the tissue study it comes from
6. 11:44, 27 Feb 2026 (diff | hist) Talk:GLP-1 receptor 748 +139 /* Bias section overstates the therapeutic case */ reply
7. 09:40, 27 Feb 2026 (diff | hist) Talk:Receptor bias 400 +148 /* Productive research, disappointing translation */ new section
8. 16:31, 26 Feb 2026 (diff | hist) Aspiration risk under anaesthesia 4,681 ±0 expand §Interpretation
9. 20:00, 2 Feb 2026 (diff | hist) Proglucagon 6,709 ±0 rm the causal claim about appetite — the cited work is associative
10. 13:10, 21 Jan 2026 (diff | hist) Talk:Triple agonist 611 +114 /* Ratio comparisons across publications */ reply
11. 11:07, 15 Jan 2026 (diff | hist) Receptor bias 4,477 ±0 give the magnitude of the incretin effect as a percentage of the insulin response
12. 04:36, 16 Oct 2025 (diff | hist) Lixisenatide 4,195 ±0 the half-life in the lead was the terminal figure; label it as such
13. 00:45, 14 Sep 2025 (diff | hist) Aspiration risk under anaesthesia 4,681 ±0 add the citation for the gallbladder finding
14. 18:51, 12 Jul 2025 (diff | hist) Receptor bias 4,000 ±0 add see also to the sister hormone
15. 02:58, 29 Jun 2025 (diff | hist) Research use only 7,423 ±0 m rm the speculation about future scheduling
16. 03:54, 4 Jun 2025 (diff | hist) Beta cell function 5,751 +813 m fix a broken wikilink
17. 03:56, 29 Apr 2025 (diff | hist) Hunan Aslsen Technology 10,064 +1,060 add the research-use-only statement to the lead rather than only the footer
18. 18:01, 5 Apr 2025 (diff | hist) Fasting insulin 3,216 +254 m add category for laboratory medicine
19. 02:20, 13 Jan 2025 (diff | hist) Gastric emptying 4,636 +660 m add the citation for the co-secretion finding
20. 21:15, 8 Jan 2025 (diff | hist) GLP-1 receptor agonist 8,171 +49 m attribute the mechanism claim to the review rather than stating it flatly
21. 21:21, 14 Dec 2024 (diff | hist) Enteroendocrine L cell 3,466 +115 m add the species in which the knockout work was done
22. 19:52, 12 Nov 2024 (diff | hist) Arcuate nucleus 3,033 +333 add the cleavage site by residue number
23. 09:06, 29 Oct 2024 (diff | hist) Proglucagon 3,438 +363 consistent en dashes in ranges
24. 18:20, 22 Oct 2024 (diff | hist) Incretin effect 4,860 +57 correct the direction of the effect on gastric emptying
25. 00:57, 26 Sep 2024 (diff | hist) Limit of detection 2,589 +32 space between number and unit per PP:MOS
26. 15:52, 13 Sep 2024 (diff | hist) Dipeptidyl peptidase-4 3,295 ±0 expand §Catalytic action and substrate range
27. 23:18, 10 Sep 2024 (diff | hist) Glucose-dependent insulinotropic polypeptide 5,034 +688 clarify that concentrations differ substantially between assay platforms
28. 18:25, 21 Aug 2024 (diff | hist) Insulin secretion 2,360 +814 clarify that concentrations differ substantially between assay platforms